Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor

Valentin Letailleur, Maxime Jullien, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Sophie Vantyghem, Aude-Marie Fourmont, Thierry Guillaume, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2024-203972

Published: 2024

Journal Articles

Chronic Myelomonocytic Leukemia Associated Adult Langerhans Cell Histiocytosis: A Descriptive and Comparative Study

Eva Chauvel, Jean-François Emile, Alice Garnier, Simon Bouzy, Sebastien Barbarot, Eric Lagrue, Antoine Neel

Blood (2024) 144 (Supplement 1): 6733.

https://doi.org/10.1182/blood-2024-200371

Published: 2024

Journal Articles

Reconstitution and Licensing of Natural Killer Cells Following T-Cell Replete Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide and Antithymocyte Globulin

Maxime Jullien, Catherine Willem, Perla Salameh, Enora Ferron, Alice Garnier, Pierre Peterlin, Amandine Le Bourgeois, Thierry Guillaume, Katia Gagne, Patrice Chevallier, Christelle Retiere

Blood (2024) 144 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2024-202902

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study

Lionel Ades, Thomas Cluzeau, Thibault Comont, Lorea Aguinaga, Aspasia Stamatoullas, Mathieu Meunier, Emmanuel Gyan, Alice Garnier, Maud D'Aveni, Sylvain Thépot, Marie Sebert, Marius Moldovan, Anouk Walter Petrich, Karine Lemarie, Fatiha Chermat, Michaela Fontenay, Sylvie Chevret, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 351.

https://doi.org/10.1182/blood-2024-204791

Published: 2024

Journal Articles

Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial

Blood (2024) 144 (Supplement 1): 349.

https://doi.org/10.1182/blood-2024-194510

Published: 2024

Journal Articles

Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center

Flore Sicre de Fontbrune, Edouard Forcade, Louis Terriou, Alice Garnier, Vincent Alcazer, Nicolas Daguindau, Lynda Maafa, Isabelle Brindel, Regis Peffault de Latour, Sylvie Chevret

Blood (2024) 144 (Supplement 1): 1321.

https://doi.org/10.1182/blood-2024-199472

Published: 2024

Journal Articles

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study

Uwe Platzbecker, Steven W Lane, Alice Garnier, Thomas Cluzeau, Odile Rauzy, Katharina S. S. Götze, Aristoteles Giagounidis, Deepak Singhal, Aicha Kopecky, Fatiha Chermat, Lionel Ades

Blood (2024) 144 (Supplement 1): 3222.

https://doi.org/10.1182/blood-2024-194185

Published: 2024

Journal Articles

Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies

Laura Prin Felix, Maxime Jullien, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Sophie Vantyghem, Aude-Marie Fourmont, Thierry Guillaume, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 4882.

https://doi.org/10.1182/blood-2024-203266

Published: 2024

Journal Articles

Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Mathilde Bastien, Maxime Jullien, Nicolas Vallet, Aline Schmidt, Tony Marchand, Amandine Le Bourgeois, Alice Garnier, Sophie Vantyghem, Aude-Marie Fourmont, Corentin Orvain, Marc Bernard, Thierry Guillaume, Jean-Baptiste Méar, Mathilde Hunault, Emmanuel Gyan, Pierre Peterlin, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 1531.

https://doi.org/10.1182/blood-2024-201589

Published: 2024

Journal Articles

Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study

Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Maxime Jullien, Chloe Antier, Thierry Guillaume, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 6963.

https://doi.org/10.1182/blood-2023-179861

Published: 2023

Journal Articles

A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial

Patrice Chevallier, Anne Thiebaut, Sylvie François, Sylvain Chantepie, Marie Thérèse Rubio, Hélène Labussière-Wallet, Eolia Brissot, Natacha Maillard, Anne Huynh, Valerie Coiteux, Alice Garnier, Amandine Le Bourgeois, Pierre Peterlin, Thierry Guillaume

Blood (2023) 142 (Supplement 1): 4957.

https://doi.org/10.1182/blood-2023-179734

Published: 2023

Journal Articles

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Blood (2023) 142 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2023-173379

Published: 2023

Journal Articles

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Blood (2023) 142 (Supplement 1): 975.

https://doi.org/10.1182/blood-2023-173518

Published: 2023

Journal Articles

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Thibault Comont, Olivier Kosmider, Mael Heiblig, Benjamin Terrier, Didier Bouscary, Guillaume Le Guenno, Roderau Outh, Maxime Samson, Achille Aouba, Estibaliz Lazarro, Odile Rauzy, Lucie Rigolot, Pierre Peterlin, Alexandre Maria, Edouard Flammarion, Alice Garnier, Benoit De Renzis, Shanti Natarajan, Benjamin Carpentier, Marielle Roux-Sauvat, Jose Torregrosa, Fabienne Closs-Prophette, Julien Rossignol, Nicolas Schleinitz, Celine Dieval, Jonahan Broner, Marie-Pierre Gourin, Gaetan Sauvetre, Benoit Faucher, Julien Vinit, Sylvie Grosleron, Alexis Mathian, Louis Terriou, Cyrille Coustal, Philippe Guilpain, Paola Marianetti-Guingel, Holy Bezanahary, Norbert Vey, Bilal Mohty, Thomas Moulinet, Vincent Grobost, Sophie Dimicoli, Benoit Suzon, Antoinette Perlat, Pierre Hirsh, Lise Larcher, Lin Pierre Zhao, Sophie Georgin-Lavialle, Arsene Mekinian, Pierre Fenaux, Vincent Jachiet, French VEXAS study group, Minhemon French Network of immune disorders associated with hemopathies, GFM Groupe Francophone des Myélodysplasies

Blood (2023) 142 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2023-178125

Published: 2023

Journal Articles

Pre-Graft Vaccination or Infection Do Not Provide More Protection Against COVID-19 Infections in Post-Graft Vaccinated Recipients of Allogeneic Stem Cell Transplantation

Valentin Letailleur, Amandine Le Bourgeois, Thierry Guillaume, Alice Garnier, Pierre Peterlin, Maxime Jullien, Chloe Antier, Marie-Christine Béné, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 4941.

https://doi.org/10.1182/blood-2023-179991

Published: 2023

Journal Articles

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

Blood (2023) 142 (Supplement 1): 3530.

https://doi.org/10.1182/blood-2023-180581

Published: 2023

Journal Articles

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Marie Anne Hospital, Thomas Cluzeau, Alice Garnier, Giovanni Marconi, Emmanuelle Tavernier, Sylvain Thepot, Aspasia Stamatoullas, Cristina Papayannidis, Sophie Park, Noemie Bigot, Lamya AIT SI Selmi, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux

Blood (2023) 142 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2023-185609

Published: 2023

Journal Articles

Pre-Graft Immune Status Predicts Survivals and Relapse in Adults Receiving Matched Peripheral Blood Stem Cell Allotransplants for Myeloid Malignancies

Maxime Jullien, Baptiste Le Calvez, Amandine Le Bourgeois, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 3622.

https://doi.org/10.1182/blood-2023-189241

Published: 2023

Journal Articles

Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms

Yannick LE Bris, Romain Madeuf, Catherine Godon, Olivier Pichon, Pierre Peterlin, Alice Garnier, Patrice Chevallier, Simon Bouzy, Marion Eveillard, Marie-Christine Béné, Olivier Theisen, Faeseh vasheghani Farahani

Blood (2023) 142 (Supplement 1): 6051.

https://doi.org/10.1182/blood-2023-188581

Published: 2023

NARROW

Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor

Chronic Myelomonocytic Leukemia Associated Adult Langerhans Cell Histiocytosis: A Descriptive and Comparative Study

Reconstitution and Licensing of Natural Killer Cells Following T-Cell Replete Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide and Antithymocyte Globulin

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study

Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial

Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study

Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies

Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study

A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Pre-Graft Vaccination or Infection Do Not Provide More Protection Against COVID-19 Infections in Post-Graft Vaccinated Recipients of Allogeneic Stem Cell Transplantation

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Pre-Graft Immune Status Predicts Survivals and Relapse in Adults Receiving Matched Peripheral Blood Stem Cell Allotransplants for Myeloid Malignancies

Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only